Silence Therapeutics (SLNCF) Equity Ratio (2019 - 2025)
Historic Equity Ratio for Silence Therapeutics (SLNCF) over the last 7 years, with Q3 2025 value amounting to 0.5.
- Silence Therapeutics' Equity Ratio fell 1235.62% to 0.5 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.5, marking a year-over-year increase of 22703.26%. This contributed to the annual value of 0.66 for FY2024, which is 25921.9% up from last year.
- Latest data reveals that Silence Therapeutics reported Equity Ratio of 0.5 as of Q3 2025, which was down 1235.62% from 0.57 recorded in Q2 2025.
- Silence Therapeutics' 5-year Equity Ratio high stood at 0.66 for Q4 2024, and its period low was 0.05 during Q1 2022.
- For the 5-year period, Silence Therapeutics' Equity Ratio averaged around 0.36, with its median value being 0.23 (2021).
- In the last 5 years, Silence Therapeutics' Equity Ratio crashed by 1588.58% in 2021 and then skyrocketed by 35116.72% in 2024.
- Quarter analysis of 5 years shows Silence Therapeutics' Equity Ratio stood at 0.09 in 2021, then surged by 131.65% to 0.21 in 2022, then dropped by 11.49% to 0.18 in 2023, then surged by 263.95% to 0.66 in 2024, then dropped by 23.71% to 0.5 in 2025.
- Its Equity Ratio was 0.5 in Q3 2025, compared to 0.57 in Q2 2025 and 0.61 in Q1 2025.